Introduction: Invasive aspergillosis (IA) is associated with a significant clinical and
Deterministic and probabilistic sensitivity analyses (DSA and PSA) were conducted.
Results: Base case analysis showed that isavuconazole was associated with a $7418 lower total cost per patient than voriconazole.
In both incremental costs per death avoided and incremental costs per additional clinical responder, isavuconazole dominated voriconazole. Results were robust in sensitivity analysis. Isavuconazole was cost saving and dominant vs. voriconazole in most DSA. In PSA, isavuconazole was cost saving in 80.2% of the simulations and cost-effective in 82.0% of the simulations at the $50,000 willingness to pay threshold per additional outcome.
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INTRODUCTION
Invasive aspergillosis (IA) is a fungal infection that primarily affects immunocompromised individuals. In 2013, a total of 2990 hospitalizations with a primary diagnosis of IA, and 14,470 hospitalizations with either a primary or secondary diagnosis of IA, occurred in the USA [1] . Risk factors for IA include the presence of hematological malignancies, hematopoietic stem cell or solid organ transplant, severe and/or prolonged neutropenia, prolonged and/or high-dose immunosuppressive therapy, and chemotherapy [2] . The majority of cases of IA are encountered in patients with hematological malignancies and bone marrow transplant patients (43.0-68.0%), with the remainder of cases occurring in solid organ transplant recipients (13.0-17.0%) and other immunocompromised hosts (10.0-15.0%) [3, 4] .
IA is a serious, life-threatening condition. The reported 1-year overall survival rate following a diagnosis of IA among bone marrow transplant patients ranges from 10.0 to 40.0% in the literature [5, 6] . Among critically ill patients admitted to an intensive care unit with proven IA, overall survival rates at 84 days after diagnosis of IA have been reported to be 21.0% [7] . A 2010 analysis of a national hospital administrative database found that the median length of hospitalization among patients diagnosed with IA was 18-26 days (depending on whether IA was a primary or secondary diagnosis) [8] [11, 12] . Voriconazole, an antifungal triazole that inhibits fungal respiration and cell membrane function, is currently the preferred agent for first-line treatment of IA, both from a clinical [11] and an economic perspective [13, 14] . Amphotericin B has a less favorable safety profile [15] and lower efficacy [15] compared to voriconazole, and it is recommended for patients who cannot be treated with voriconazole [11] . Other available agents offer limited efficacy benefits compared to voriconazole and therefore are recommended as salvage therapy agents after voriconazole or amphotericin B treatment [11] . A literature review conducted by Krueger and Nelson identified 10 pharmacoeconomic analyses in six different countries comparing voriconazole to other options for the treatment of IA, and all these analyses concluded that voriconazole was the most cost-effective therapy compared to other treatment options discussed above [13] . Another advantage of voriconazole is that it can be administered both orally and intravenously (IV). Voriconazole does present several possible disadvantages: possible toxicity of the IV formulation in patients with renal failure (due to required co-administration with solubility additive sulfobutylether-b-cyclodextrin) [11, 14] , a twice daily dosing schedule of the oral medication because of relatively rapid metabolization [14] , and a known risk of drug-drug interactions (due to its effect on the CYP2C19, CYP2C9, and CYP3A4 metabolic pathways) [11, 14] .
Isavuconazonium sulfate, a novel triazole and prodrug of isavuconazole, received FDA approval for the treatment of IA and invasive mucormycosis in March 2015 [16] . The approval was granted on the basis of data from the SECURE clinical trial (NCT00412893), which showed that isavuconazole has comparable efficacy with voriconazole [17] . All-cause mortality at day 42 (the SECURE trial primary endpoint) was similar in both treatment groups (18.6% in the isavuconazole-treated group and 20.2% in the voriconazole-treated group). Overall adverse event (AE) rates were also similar (96.1% of isavuconazole-treated patients and 98.5% of voriconazole-treated patients experienced at least one treatment-emergent AE) [17] . However, statistically significant differences were observed in eye disorders, hepatobiliary disorders, and skin disorders, with isavuconazole-treated patients having significantly lower rates of these events [17] . Similar to voriconazole, isavuconazole is also available in both oral and IV formulations. Its IV formulation, however, does not require solubility additive sulfobutylether-b-cyclodextrin, which has been associated with potential nephrotoxicity in the voriconazole IV formulation [18] . Oral isavuconazole has a longer half-life than oral voriconazole, allowing for once daily dosing. In addition, the metabolism of isavuconazole is limited to the CYP3A4 and CYP3A5 pathway [18] .
In order to determine the optimal treatment option, it is important to thoroughly and patient level data was not used.
Institutional review board (IRB) review was not needed.
Efficacy and Safety Inputs
Efficacy inputs, mortality and clinical response, for both treatment arms were extracted from the SECURE trial (Table 1 ) [17] . Mortality was the primary efficacy endpoint and clinical response was the secondary endpoint in the SECURE trial. As was previously described, all-cause mortality at day 42 was 18.6% for isavuconazole-treated patients and 20.2% for voriconazole-treated patients
Clinical response rates were 62.0% and 60.3%, respectively [adjusted difference = 0.4%, 95%
CI (-10.64, 11.53%)] [17] . The differences in these two outcomes were not statistically significant. The median length of stay of the initial hospitalization was 13 days for isavuconazole-treated patients and 15 days for voriconazole-treated patients [19] . Following This difference was not statistically significant [19] . The median length of stay for readmissions (6 days) was obtained from an analysis of the Premier database of inpatients with a diagnosis of IA and who had a readmission [20] ; in the absence of other information, it was assumed to be equal across treatment arms.
The model considered grade III and IV AEs whose overall incidence significantly differed between isavuconazoleand voriconazole-treated patients in the SECURE trial, i.e., eye disorders, hepatobiliary disorders, and skin disorders (individually described in ESM Appendix 1) [21] .
Dosing Frequency and Duration Inputs
The dosing schedules for both voriconazole and isavuconazole were based on the doses administered in the SECURE trial [17] , and they are consistent with their respective product labels [16, 22] . The current model assumed there was no vial wastage. Both isavuconazole and voriconazole were initiated as an IV infusion and could subsequently be converted to an oral formulation as early as day 3, on the basis of physician evaluation. IV voriconazole was dosed on the basis of patients' weight, while administration of oral voriconazole, IV and oral isavuconazole was based on fixed dosing. The model assumed an average patient weight of 75 kg to estimate costs of IV voriconazole, which was the midpoint of the average weight of 82 kg of adults older than 20 years of age in the USA and the mean weight of 69 kg in the SECURE trial [21] . Details regarding the dosing of each treatment arm can be found in Table 1 (Table 1 ). All costs were inflated to 2015 USD [24] .
The costs of managing AEs were estimated using published literature [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . For acute AEs, the cost of managing the entire AE episode was included and this cost was assumed to be equal among the treatment arms. For AEs which could last beyond the initial hospitalization, the cost per AE reported in literature (typically reported as an annual cost) was prorated on the basis of the length of initial hospital stay (i.e., 13 days for isavuconazole and 15 days for voriconazole) for each treatment arm. Prorating AEs this way makes the assumption that those AEs begin on the first day of IA therapy. This assumption is used given the lack of detailed information on time of AE onset and the fact that costs of AE do not have a significant impact on the model's results. When no literature was available, the cost of each AE was assumed to be the cost of an inpatient consultation of moderate complexity. In the case of hepatobiliary disorders, the cost of a liver function panel was also included.
Deterministic and Probabilistic Sensitivity Analyses (DSA and PSA)
Deterministic sensitivity analysis (DSA) was carried out by increasing and decreasing one parameter at a time while maintaining the rest of the inputs at the base case value. Treatment duration, length of hospitalization (length of stay), readmission rate, per diem cost of hospitalization, drug costs, costs of AE treatment, clinical response rates, and mortality rates were all varied in the DSA to evaluate their impact. In addition, a sensitivity analysis assuming that a US payer perspective was included. This payer perspective included drug and AE costs throughout the total duration of isavuconazole and voriconazole treatment.
The total duration was reported by Horn et al.
(including inpatient and outpatient) [19] .
Another sensitivity analysis assumed equal hospital length of stay, mortality, and clinical response rate among isavuconazole-and voriconazole-treated patients. For this analysis, the average of each input for isavuconazole and voriconazole was used for both treatments. In all PSA simulations of the total cost per patient, the incremental cost per patient 
